Clinical trials: Diabetes Management
Obesity
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU)…
- Trial name
- NCT00603291
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 604 people
- Sponsor
- Eisai Inc.
Diabetes Mellitus, Type 2, Hyperglycemia
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
This study will investigate the efficacy and safety of two doses (high and low) of empagliflozin in combination with metformin (500 mg and 1000 mg) administered twice daily in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01719003
- Testing
- Metformin 500 mg bid, Metformin 1000 mg bid, Empagliflozin low dose qd
- Where
- 190 sites in United States, Brazil and 19 more
- Volunteers
- 1,413 people
- Sponsor
- Boehringer Ingelheim
Diabetic Nephropathy
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
The study hypothesis under test is that administration of a CCR2/5 antagonist to subjects with type 2 diabetes and overt nephropathy will result in a reduction in urinary albumin, a surrogate for improved glomerular filtration.
- Trial name
- NCT01712061
- Testing
- PF-04634817
- Where
- 142 sites in United States, Argentina and 12 more
- Volunteers
- 226 people
- Sponsor
- Pfizer
Type 2 Diabetes
Linagliptin Inpatient Trial
This study is a prospective, randomized, open label trial to compare the safety and efficacy of linagliptin (an oral anti diabetic medication) given orally once daily to an insulin regimen of glargine once daily plus rapid-acting…
- Trial name
- NCT02004366
- Testing
- Linagliptin, Basal Bolus, Linagliptin + 50% Glargine dose on discharge
- Where
- 5 sites in United States
- Volunteers
- 295 people
- Sponsor
- Emory University
GDM
A Co-created Self-care and Informal Support Intervention Study Among Women With GDM in Vietnam
Gestational Diabetes Mellitus (GDM) is significant public health problem in Vietnam, which is potentially treatable if managed properly by the pregnant women once diagnosed.
- Trial name
- VALID-II (NCT05744856)
- Testing
- Self-care with informal support
- Where
- 2 sites in Vietnam
- Volunteers
- 435 people, healthy volunteers welcome
- Sponsor
- Thai Binh University of Medicine and Pharmacy
Type1 Diabetes Mellitus
The International Diabetes Closed Loop (iDCL) Trial: Protocol 1
The objective of the study is to assess the efficacy and safety of home use of a Control-to-Range (CTR) closed-loop (CL) system.
- Trial name
- iDCL (NCT02985866)
- Testing
- Artificial Pancreas, Sensor Augmented Therapy
- Where
- 7 sites in United States
- Volunteers
- 127 people
- Sponsor
- University of Virginia
Diabetes Mellitus, Surgical Procedure, Unspecified
Multifactorial Pre-operative Intervention in Diabetes Mellitus
The purpose of this study is to advance the quality of care among inpatients with diabetes in the VHA. When patients with diabetes are admitted to the hospital, there is a greater chance that they will have a complication that…
- Trial name
- NCT00753766
- Testing
- Multifactorial Intervention
- Volunteers
- 1 people
- Sponsor
- VA Office of Research and Development
Chronic Kidney Diseases, Hypertension
Chronic Kidney Disease Clinical Decision Support
To prevent serious chronic kidney disease (CKD) complications such as end-stage renal disease and cardiovascular events, better strategies are needed to identify, treat, and refer CKD patients seen in primary care clinics.
- Conditions
- Chronic Kidney Diseases, Hypertension, Diabetes
- Trial name
- CKD-CDS (NCT03890588)
- Testing
- CKD enhanced clinical decision support
- Where
- United States
- Volunteers
- 6,295 people
- Sponsor
- HealthPartners Institute